|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis - Dengue Virus Vaccines
La Merie Publishing, March 2010, Pages: 13
The present Competitive Intelligence Report about Dengue Virus Vaccines provides a competitor evaluation in the field of investigational vacciness against one or more serotypes of Dengue Virus for prophylaxis of Dengue fever as of March 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
It is estimated that about 100 million cases of infection by Dengue virus occur each year and that nearly half the world’s population is at risk of Dengue virus infection. At present, no vaccines are available to prevent infection with mosquito-borne Dengue virus. There are four serotypes of Dengue virus, and neutralizing antibodies are serotype-specific with the risk of sequential infections. Although immunity against a specific serotype is life-long, but previous infection with one serotype is a risk factor for a more severe form of Dengue (Dengue hemorrhagic fever) upon subsequent infection with another serotype, thus emphasizing the need for a tetravalent vaccine against all four serotpyes of Dengue virus.
A number of vaccines have entered clinical development, two of them (live, attenuated forms) already in large scale trials. Newer vaccines are recombinant subunit or vector-delivered DNA forms. Most of them are tetravalent vaccines aimed at all four serotypes of Dengue virus.
The report includes a compilation of currently active projects in research and development of small vaccines targeting Dengue virus for prophylaxis of Dengue fever. In addition, the report lists company-specific R&D pipelines of Dengue Virus Vaccines. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
Competitor Analysis: HPV Vaccines
Competitor Analysis - Hepatitis Vaccines
Competitor Analysis: RSV Vaccines and Therapeutics
Competitor Analysis: Cytomegalovirus (CMV) Vaccines and Therapeutics
Competitor Analysis: Anti-Infective Antibodies
Competitor Analysis: Malaria Vaccines
Competitor Analysis: Anthrax Vaccines and Therapeutics
Commercial Prospects for Dengue Vaccines
Vaccine Pipeline Database: 1-Year Subscription
|
|
|
|
